Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
Human immunoglobulin prepared for intravenous administration (IGIV) has a number of important uses in the treatment of disease. Some of these are in diseases for which acceptable treatment alternatives do not exist. In this review we have evaluated the evidence underlying a wide variety of IGIV uses and make specific recommendations on the basis of these data. Given the potential risks and inherent scarcity of IGIV, careful consideration of the indications for and administration of IGIV is warranted.
Orange
Jordan S
JS
Department of Pediatrics, University of Pennsylvania School of Medicine, The Children's Hospital of Philadelphia, Philadelphia 19104, USA. Orange@mail.med.upenn.edu
Hossny
Elham M
EM
Weiler
Catherine R
CR
Ballow
Mark
M
Berger
Melvin
M
Bonilla
Francisco A
FA
Buckley
Rebecca
R
Chinen
Javier
J
El-Gamal
Yehia
Y
Mazer
Bruce D
BD
Nelson
Robert P
RP
Patel
Dhavalkumar D
DD
Secord
Elizabeth
E
Sorensen
Ricardo U
RU
Wasserman
Richard L
RL
Cunningham-Rundles
Charlotte
C
D001249:Asthma / Q000628:therapy; D001327:Autoimmune Diseases / Q000628:therapy; D002986:Clinical Trials as Topic; D003141:Communicable Diseases / Q000628:therapy; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000628:therapy; D006084:Graft Rejection / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects; D001523:Mental Disorders / Q000628:therapy; D009422:Nervous System Diseases / Q000628:therapy; D018357:Respiratory Syncytial Virus Infections / Q000209:etiology / Q000628:therapy; D012306:Risk; D012871:Skin Diseases / Q000628:therapy
D016756:Immunoglobulins, Intravenous